Compare LPL & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPL | BEAM |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.6B |
| IPO Year | 2004 | 2019 |
| Metric | LPL | BEAM |
|---|---|---|
| Price | $3.31 | $28.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $50.75 |
| AVG Volume (30 Days) | ★ 2.9M | 1.7M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $24,000.00 |
| Revenue This Year | $1.35 | N/A |
| Revenue Next Year | $2.94 | $33.77 |
| P/E Ratio | $25.64 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $2.76 | $16.03 |
| 52 Week High | $5.83 | $38.26 |
| Indicator | LPL | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 45.99 | 52.00 |
| Support Level | $2.76 | $26.23 |
| Resistance Level | $4.37 | $28.96 |
| Average True Range (ATR) | 0.10 | 1.32 |
| MACD | 0.04 | 0.39 |
| Stochastic Oscillator | 46.96 | 80.96 |
LG Display Co Ltd manufacture TFT-LCD and OLED technology-based display panels in a broad range of sizes and specifications mainly for use in IT products (comprising notebook computers, desktop monitors and tablet computers), televisions, mobile devices, including smartphones, as well as auto products, and it are one of the world's suppliers of large-sized OLED television panels. It also manufacture display panels for industrial and other applications, including entertainment systems and medical diagnostic equipment.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.